Syndax Pharmaceuticals, Inc. Shareholders' Equity
Syndax Pharmaceuticals, Inc. (SNDX) had Shareholders' Equity of $15.10 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $15.10M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $41.62M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $64.63M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $115.43M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $15.10M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $41.62M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $64.63M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $115.43M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $157.42M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $215.06M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $288.12M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $366.43M 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $434.34M 10-Q · filed 2025-11-03 | |
| 2024-03-31 | $491.89M 10-Q · filed 2025-11-03 | |
| 2023-12-31 | $554.20M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $359.19M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $400.04M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $435.50M 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $467.45M 10-K · filed 2026-02-26 | |
| 2022-09-30 | $338.10M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $361.94M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $374.55M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $408.37M 10-K · filed 2025-03-03 | |
| 2021-09-30 | $199.00M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $214.56M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $228.21M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $252.19M 10-K · filed 2024-02-27 | |
| 2020-09-30 | $131.98M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $147.65M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $53.51M 10-Q · filed 2021-11-15 | |
| 2019-12-31 | $31.60M 10-K · filed 2023-02-28 | |
| 2019-09-30 | $44.04M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $55.27M 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $68.63M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $53.05M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $64.27M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $70.35M 10-Q · filed 2019-11-07 | $70.35M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $86.95M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $104.32M 10-K · filed 2021-03-12 | |
| 2017-09-30 | $96.71M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $109.34M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $72.61M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $84.14M 10-K · filed 2020-03-05 | |
| 2016-09-30 | $93.83M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $106.24M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $113.85M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | -$252.41M 10-K · filed 2019-03-07 | |
| 2014-12-31 | -$152.57M 10-K · filed 2018-03-08 | |
| 2013-12-31 | -$128.47M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |